手握强度和心力衰竭患者的预后:一个元分析
Yu Wang1, Xuehua Pu1, Zhiyun Zhu1
1Department of Critical Care Medicine, Taizhou People's Hospital, Taizhou, Jiangsu Province, China.
Clinical cardiology
|July 20, 2023
概括
在心力衰竭 (HF) 患者中,手握强度 (HGS) 降低与较高的死亡风险有关. 这一系统性审查证实,低HGS是HF预后不佳的重要预测因素.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 公共卫生 公共卫生
背景情况:
- 肌肉力量的减少,特别是手握力 (HGS),是被诊断为心力衰竭 (HF) 的患者的一个普遍问题.
- 作为HF患者预后指标的HGS的临床意义需要进行彻底的调查.
研究的目的:
- 系统地审查和进行一项元分析,评估手握强度 (HGS) 与心力衰竭 (HF) 患者的预后之间的关联.
- 为了确定降低HGS是否是HF患者不良结果的危险因素.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane Library,Web of Science) 进行了全面的文献搜索,以确定具有纵向随访的相关观察研究.
- 采用随机效应模型,综合了来自15项纳入研究的数据,其中包括7350名患有高血压的患者.
主要成果:
- 在HF患者中,较低的HGS与死亡风险增加显著相关 (RR: 2.00,95% CI: 1.55-2.58).
- 每一公斤体重下降的HGS与死亡风险上升8%相关 (RR:1.08,95% CI:1.05-1.11).
- 降低HGS也与复合结局的高风险有关,即HF再住院或死亡率 (RR: 1.67,95% CI: 1.19-2.35).
结论:
- 低握力 (HGS) 是与心力衰竭 (HF) 患者的不良临床结果相关的重要指标,包括死亡率和再住院,心力衰竭 (HF) 患者.
- 这些发现强调了评估HGS作为心力衰竭管理中的预后工具的重要性.
相关概念视频
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:30Heart Failure VII: Nursing Interventions
98
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
98
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Heart Failure IV: Classification and Diagnostic Evaluation
20
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16